AustriaAustria

Apeiron licences immunocancer biologic from Merck

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to melanoma, neuroblastoma and other tumour cells expressing the GD2 antigen and mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) through its antibody function. Through its cytokine moiety, it mediates NK- and T-cell dependent cellular immune responses against tumour cells. In a small Phase II study, approx 27% of a subgroup of children with neuroblastoma showed complete response over 35 months. Apeiron said that it will continue clinical development to further investigate the protein's therapeutic potential in this indication, an incurable cancer with poor prognosis. With the drug candidate, Apeiron will fuel its pipeline of proprietary drug candidates after it has licensed out its lead product APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2) for treatment of Acute Respiratory Distress Syndrome to GlaxoSmithKline in March 2010.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/apeiron-licences-immunocancer-biologic-from-merck.html

Product of the week

Products

Events

All Events

Current issue

All issues